MA33181B1 - Dérivés de pyrrolo [2,3-b]pyridine pour l'inhibition des kinases raf - Google Patents

Dérivés de pyrrolo [2,3-b]pyridine pour l'inhibition des kinases raf

Info

Publication number
MA33181B1
MA33181B1 MA34228A MA34228A MA33181B1 MA 33181 B1 MA33181 B1 MA 33181B1 MA 34228 A MA34228 A MA 34228A MA 34228 A MA34228 A MA 34228A MA 33181 B1 MA33181 B1 MA 33181B1
Authority
MA
Morocco
Prior art keywords
pyrrolo
pyridine
difluoro
carbonyl
phenyl
Prior art date
Application number
MA34228A
Other languages
Arabic (ar)
English (en)
Inventor
Prabha N Ibrahim
Wayne Spevak
Hanna Cho
Hongyao Zhu
Original Assignee
Plexxikon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Plexxikon Inc filed Critical Plexxikon Inc
Publication of MA33181B1 publication Critical patent/MA33181B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'INVENTION CONCERNE LE PROPANE-1-ACIDE SULFONIQUE {2,4-DIFLUORO-3-[5-(2-MÉTHOXY-PYRIMIDINE-5-YL)-1H-PYRROLO[2,3-B]PYRIDINE-3-CARBONYL]-PHÉNYL}-AMIDE, LE PROPANE-1-ACIDE SULFONIQUE [3-(5-CYANO-1H-PYRROLO[2,3-B]PYRIDINE-3-CARBONYL)-2,4-DIFLUORO-PHÉNYL]-AMIDE,LE PROPANE-1-ACIDE SULFONIQUE [3-(5-CYANO-1H-PYRROLO[2,3-B]PYRIDINE-3-CARBONYL)-2-FLUORO-PHÉNYL]-AMIDE, LE N-[3-(5-CYANO-1H-PYRROLO[2,3-B] PYRIDINE-3-CARBONYL)-2,4-DIFLUORO-PHÉNYL]-2,5-DIFLUORO-BENZÈNESULFONAMIDE,LE N-[3-(5-CYANO-1H-PYRROLO[2,3-B] PYRIDINE-3-CARBONYL)-2,4-DIFLUORO-PHÉNYL]-3-FLUORO-BENZÈNESULFONAMIDE, LE PYRROLIDINE-1-ACIDE SULFONIQUE [3-(5-CYANO-1H-PYRROLO[2,3-B] PYRIDINE-3-CARBONYL)-2,4-DIFLUORO-PHÉNYL]-AMIDE, LE N,N-DIMÉTHYLAMINO-ACIDE SULFONIQUE [3-(5-CYANO-1H-PYRROLO[2,3-B]PYRIDINE-3-CARBONYL)-2,4-DIFLUORO-PHÉNYL]-AMIDE, ET LEURS SELS, LEURS FORMULATIONS, LEURS CONJUGUÉS, LEURS DÉRIVÉS, LEURS FORMES ET LEURS UTILISATIONS. DANS CERTAINS ASPECTS ET MODES DE RÉALISATION, LES COMPOSÉS SELON L'INVENTION OU LEURS SELS, LEURS FORMULATIONS, LEURS CONJUGUÉS, LEURS DÉRIVÉS, ET LEURS FORMES SONT ACTIFS SUR AU MOINS UNE PROTÉINE KINASE RAF. L'INVENTION CONCERNE ÉGALEMENT LEURS PROCÉDÉS D'UTILISATION POUR TRAITER DES MALADIES ET DES ÉTATS, Y COMPRIS DES MALADIES ET ÉTATS ASSOCIÉS À L'ACTIVITÉ DES PROTÉINES KINASES RAF, NOTAMMENT LE MÉLANOME, LE GLIOME, LE CANCER COLORECTAL, LE CANCER DE LA THYROÏDE, LE CANCER DU POUMON, LE CANCER DE L'OVAIRE, LE CANCER DE LA PROSTATE, ET LE CANCER DU TRACTUS BILIAIRE.
MA34228A 2009-03-11 2010-03-10 Dérivés de pyrrolo [2,3-b]pyridine pour l'inhibition des kinases raf MA33181B1 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US15939009P 2009-03-11 2009-03-11
US15939209P 2009-03-11 2009-03-11
US15940009P 2009-03-11 2009-03-11
US15939609P 2009-03-11 2009-03-11
US15940209P 2009-03-11 2009-03-11
US15940609P 2009-03-11 2009-03-11
US15939509P 2009-03-11 2009-03-11
PCT/US2010/026816 WO2010104945A1 (fr) 2009-03-11 2010-03-10 Dérivés de pyrrolo [2, 3-b] pyridine pour l'inhibition des kinases raf

Publications (1)

Publication Number Publication Date
MA33181B1 true MA33181B1 (fr) 2012-04-02

Family

ID=42199540

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34228A MA33181B1 (fr) 2009-03-11 2010-03-10 Dérivés de pyrrolo [2,3-b]pyridine pour l'inhibition des kinases raf

Country Status (23)

Country Link
US (1) US8901301B2 (fr)
EP (1) EP2406259A1 (fr)
JP (1) JP2012520307A (fr)
KR (1) KR101663339B1 (fr)
CN (1) CN102421776A (fr)
AR (1) AR075812A1 (fr)
AU (1) AU2010224245B2 (fr)
BR (1) BRPI1011515A2 (fr)
CA (1) CA2755045A1 (fr)
CO (1) CO6620074A2 (fr)
CR (1) CR20110476A (fr)
EC (1) ECSP11011313A (fr)
MA (1) MA33181B1 (fr)
MX (1) MX2011009489A (fr)
MY (1) MY161861A (fr)
NI (1) NI201100168A (fr)
NO (1) NO20111241A1 (fr)
PE (1) PE20120184A1 (fr)
RU (1) RU2011141123A (fr)
SG (2) SG10201402977WA (fr)
TW (1) TW201036973A (fr)
WO (1) WO2010104945A1 (fr)
ZA (1) ZA201106599B (fr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063888A2 (fr) 2006-11-22 2008-05-29 Plexxikon, Inc. Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées
WO2009012283A1 (fr) 2007-07-17 2009-01-22 Plexxikon Inc. Composés et procédés pour la modulation des kinases et leurs indications
WO2009143018A2 (fr) 2008-05-19 2009-11-26 Plexxikon, Inc. Composés et procédés de modulation des kinases, et indications associées
US8592448B2 (en) 2008-11-20 2013-11-26 OSI Pharmaceuticals, LLC Substituted pyrrolo[2,3-b]-pyridines and -pyrazines
MY172424A (en) 2009-04-03 2019-11-25 Hoffmann La Roche Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof
CN106220623A (zh) 2009-11-06 2016-12-14 普莱希科公司 用于激酶调节的化合物和方法及其适应症
ES2627911T3 (es) 2009-11-18 2017-08-01 Plexxikon, Inc. Derivados de N-[2-fluoro-3-(4-amino-7H-pirrolo[2,3-d]pirimidin-5-carbonil)-fenil]-4-bencenosulfonamida como moduladores de la proteína quinasa Raf para el tratamiento del cáncer
BR112012015745A2 (pt) * 2009-12-23 2016-05-17 Plexxikon Inc compostos e métodos para a modulação de quinase, e indicações dos mesmos
TWI510487B (zh) 2010-04-21 2015-12-01 Plexxikon Inc 用於激酶調節的化合物和方法及其適應症
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
EP2569315A1 (fr) 2010-05-14 2013-03-20 OSI Pharmaceuticals, LLC Inhibiteurs de kinases bicycliques fusionnés
WO2012075327A1 (fr) 2010-12-02 2012-06-07 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Méthodes de traitement d'une tumeur au moyen d'un anticorps qui se lie spécifiquement à grp94
US9624213B2 (en) * 2011-02-07 2017-04-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
EP2701694A4 (fr) 2011-04-28 2014-10-08 Univ Duke Procédés de traitement d'hémoglobinopathies
JP6113151B2 (ja) 2011-05-17 2017-04-12 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼ調節およびその適応症
US9988687B2 (en) * 2011-09-20 2018-06-05 The George Washington Univeristy Companion diagnostics for cancer and screening methods to identify companion diagnostics for cancer based on splicing variants
US9249110B2 (en) 2011-09-21 2016-02-02 Neupharma, Inc. Substituted quinoxalines as B-raf kinase inhibitors
US20130172375A1 (en) 2011-12-13 2013-07-04 Hoffmann-La Roche Inc. Pharmaceutical composition
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
US9150570B2 (en) * 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
TWI601725B (zh) 2012-08-27 2017-10-11 加拓科學公司 取代的氮雜吲哚化合物及其鹽、組合物和用途
EP2892534B8 (fr) 2012-09-06 2021-09-15 Plexxikon Inc. Composés et procédés pour la modulation des kinases, et leurs indications
WO2014081760A1 (fr) 2012-11-20 2014-05-30 Duke University Procédés de traitement d'hémoglobinopathies
MX365640B (es) 2012-12-21 2019-06-10 Plexxikon Inc Compuestos y metodos para la modulacion de quinasas y sus indicaciones.
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
DK2970265T3 (en) 2013-03-15 2018-10-01 Plexxikon Inc HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF
KR20160061911A (ko) 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
CN105228983A (zh) 2013-05-30 2016-01-06 普莱希科公司 用于激酶调节的化合物及其适应症
AU2015206603B9 (en) 2014-01-14 2019-07-18 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms
US9771369B2 (en) 2014-03-04 2017-09-26 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
ES2774177T3 (es) 2014-09-15 2020-07-17 Plexxikon Inc Compuestos heterocíclicos y usos de estos
CA2963091A1 (fr) 2014-10-06 2016-04-14 Dana-Farber Cancer Institute, Inc. Biomarqueurs a base d'angiopoietine -2 utilises pour la prediction de la reponse de point de controle anti-immunitaire
WO2016164641A1 (fr) 2015-04-08 2016-10-13 Plexxikon Inc. Composés et méthodes de modulation des kinases, et leurs indications
JP6530826B2 (ja) 2015-05-06 2019-06-12 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼを修飾する１ｈ−ピロロ［２，３−ｂ］ピリジン誘導体の合成
LT3292123T (lt) 2015-05-06 2020-12-28 Plexxikon Inc. Junginio, moduliuojančio kinazes, kietos formos
US10829484B2 (en) 2015-07-28 2020-11-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
ES2913048T3 (es) 2015-09-21 2022-05-31 Opna Immuno Oncology Sa Compuestos heterocíclicos y usos de estos
MX2018006856A (es) 2015-12-07 2018-08-01 Plexxikon Inc Compuestos y metodos para modulacion de la quinasa, e indicaciones de los mismos.
ES2904615T3 (es) 2016-03-16 2022-04-05 Plexxikon Inc Compuestos y métodos para la modulación de quinasas e indicaciones al respecto
TW201815766A (zh) 2016-09-22 2018-05-01 美商普雷辛肯公司 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症
EP3558991A2 (fr) 2016-12-23 2019-10-30 Plexxikon Inc. Composés et procédés pour la modulation de cdk8, et indications associées
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
JP2020511467A (ja) 2017-03-20 2020-04-16 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． ブロモドメインを阻害する４−（１−（１，１−ジ（ピリジン−２−イル）エチル）−６−（３，５−ジメチルイソオキサゾール−４−イル）−１Ｈ−ピロロ［３，２−ｂ］ピリジン−３−イル）安息香酸の結晶形
WO2018226846A1 (fr) 2017-06-07 2018-12-13 Plexxikon Inc. Composés et procédés de modulation de kinase
AU2018307910B2 (en) 2017-07-25 2024-07-25 Daiichi Sankyo Company, Limited Formulations of a compound modulating kinases
US10717735B2 (en) 2017-10-13 2020-07-21 Plexxikon Inc. Solid forms of a compound for modulating kinases
AU2018354423B2 (en) 2017-10-27 2024-11-07 Plexxikon Inc. Formulations of a compound modulating kinases
NZ766594A (en) 2018-01-31 2025-12-19 Heparegenix Gmbh Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
EP3768666A1 (fr) 2018-03-20 2021-01-27 Plexxikon Inc. Composés et procédés de modulation d'ido et de tdo, et indications pour ceux-ci
GB201809460D0 (en) * 2018-06-08 2018-07-25 Crt Pioneer Fund Lp Salt form
EP3810139A1 (fr) 2018-06-21 2021-04-28 HepaRegeniX GmbH Inhibiteurs de protéine kinase tricycliques pour favoriser la régénération du foie ou réduire ou prévenir la mort des hépatocytes
IL279641B2 (en) 2018-07-16 2024-04-01 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
SG11202110714VA (en) 2019-04-09 2021-10-28 Plexxikon Inc Condensed azines for ep300 or cbp modulation and indications therefor
US12509444B2 (en) 2019-12-06 2025-12-30 Plexxikon Inc. Compounds and methods for CD73 modulation and indications therefor
CA3164361A1 (fr) 2020-01-15 2021-07-22 Heparegenix Gmbh Derives de 3-benzoyl-1h-pyrrolo[2,3-b]pyridine utilises en tant qu'inhibiteurs de mkk4 pour le traitement de maladies du foie
US11807626B2 (en) 2020-04-23 2023-11-07 Opna Bio SA Compounds and methods for CD73 modulation and indications therefor
WO2021222442A1 (fr) 2020-04-29 2021-11-04 Plexxikon Inc. Synthèse de composés hétérocycliques
JP2023530030A (ja) 2020-06-19 2023-07-12 シーフォー セラピューティクス， インコーポレイテッド Ｂｒａｆ分解剤
TW202227068A (zh) 2020-08-21 2022-07-16 美商普雷辛肯公司 組合藥物療法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2377318T3 (es) 2002-09-06 2012-03-26 Cerulean Pharma Inc. Polímeros a base de ciclodextrina para el suministro de los agentes terapéuticos enlazados covalentemente a ellos
UA95244C2 (ru) * 2005-06-22 2011-07-25 Плексикон, Инк. Соединения и способ модулирования активности киназ, и показания для их применения
PE20121126A1 (es) * 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa

Also Published As

Publication number Publication date
KR101663339B1 (ko) 2016-10-06
KR20110125670A (ko) 2011-11-21
RU2011141123A (ru) 2013-04-20
ZA201106599B (en) 2014-02-26
CN102421776A (zh) 2012-04-18
EP2406259A1 (fr) 2012-01-18
NO20111241A1 (no) 2011-09-28
SG10201402977WA (en) 2014-09-26
CA2755045A1 (fr) 2010-09-16
JP2012520307A (ja) 2012-09-06
MX2011009489A (es) 2011-10-11
PE20120184A1 (es) 2012-03-28
CR20110476A (es) 2012-01-04
AR075812A1 (es) 2011-04-27
MY161861A (en) 2017-05-15
CO6620074A2 (es) 2013-02-15
BRPI1011515A2 (pt) 2016-03-29
AU2010224245A1 (en) 2011-09-29
WO2010104945A1 (fr) 2010-09-16
US8901301B2 (en) 2014-12-02
US20100286178A1 (en) 2010-11-11
SG174257A1 (en) 2011-10-28
ECSP11011313A (es) 2011-10-31
TW201036973A (en) 2010-10-16
NI201100168A (es) 2012-01-11
AU2010224245B2 (en) 2016-07-21

Similar Documents

Publication Publication Date Title
MA33181B1 (fr) Dérivés de pyrrolo [2,3-b]pyridine pour l'inhibition des kinases raf
WO2007120883A3 (fr) Compositions et leurs utilisations sur l'hepcidine
DE602005024279D1 (de) 5-substituierte-2-phenylaminobenzamide als mek-inhibitoren
NO20091509L (no) Substituerte tetrahydropyrrolopyrazinforbindelser med affinitet KCNQ2/3 K+ kanal og anvendelse derav i medikamenter
PA8637601A1 (es) Compuestos moduladores de la actividad de c-kit y usos de los mismos
EA200801551A1 (ru) Применение сульфонамидных производных в лечении расстройств метаболизма и нервной системы
NO20075111L (no) Farmasoytisk sammensetning
NO20071843L (no) Substituerte anilinderivater
WO2006031291A3 (fr) Nouvelle classe de molecules a base de proteines therapeutiques
WO2006012642A3 (fr) Derives de pyrrole en tant qu'agents pharmaceutiques
MA33811B1 (fr) Composés et méthodes utilisés pour la modulation kinases et indications à cet effet
NO20076659L (no) Pyrrolo(2,3-B)pyridinderivater som protein kinase inhibitorer
MA30291B1 (fr) Derives de l'azolopyridin-3-one en tant qu'inhibiteurs de la lipase endotheliale
MY141196A (en) Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
EP2131848A4 (fr) Compositions et methodes de potentialisation de l'activite de molecules biologiquement actives
NO2008019I1 (no) N-[2-(dietylamino)etyl]-5-[(Z)-(5-fluoro-2-okso-L,2-dihydro-3H-indol-3-yliden)metyl]-2,4-dimetyl-LH-pyrrol-3-karboksamid (sunitinib),samt farmasoeytisk akseptable salter
EA200300793A1 (ru) Производные 3-(4-амидопиррол-2-илметилиден)-2-индолинона в качестве ингибиторов протеинкиназ
ATE547420T1 (de) Azepinoindol und pyridoindolderivate als pharmazeutische mittel
NO20083324L (no) Multisykliske aminosyrederivater og anvendelse derav
MA28279A1 (fr) Derives d'indole et utilisation de ceux-ci comme inhibiteurs de kinase, notamment des inhibiteurs de ikk2
MA28370A1 (fr) Derives de alkylpiperazine-et alkylhomopiperazine-carboxylates, leur preparation et leur application en tant qu'inhibiteurs de l'enzyme faah
WO2003063787A3 (fr) Analogues non steroidiens de 2-methoxyestradiol
MA28366A1 (fr) Derives de piperidinylalkylcarbamates, leur preparation et leur application comme inhibiteurs de l'enzyme faah
NO20081713L (no) Pyrimidinderivater og deres anvendelse som KCNQ-kaliumkanalapnere
EA200600468A1 (ru) Биполярные транс-каротиноидные соли и их применение